2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1414

Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Prior Treatment With Methotrexate
Abstract Number: 435

Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Methotrexate-naïve Patients With Rheumatoid Arthritis
Abstract Number: 2325

Final 5-Year Safety and Efficacy Results Of a Phase 3, Randomized, Placebo-Controlled Trial Of Golimumab In Patients With Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy
Abstract Number: 1883

Fine Mapping and Expression Of a Locus Overlapping 3 Types Of Inflammatory Arthritis
Abstract Number: 1706

Fine-Mapping Major Histocompatibility Complex Variation Associated With Ankylosing Spondylitis Susceptibility
Abstract Number: 2830

First Stage Of a Simon’s Two-Stage Optimal Approach Supports Placental Transfer Of Hydroxychloroquine and a Reduced Recurrence Rate Of The Cardiac Manifestations Of Neonatal Lupus
Abstract Number: 500

Fixed Versus On-Flare Retreatment With Rituximab In RA – Results From The Cererra Collaboration
Abstract Number: 558

Fli-1 Regulates Immune Cell Infiltration Through Affecting Local Chemokine Expression and IL-6 Expression In The Kidney Of Lupus Prone Mice
Abstract Number: 2706

Fli1 Haploinsufficiency Exacerbates Dermal Fibrosis Via Activation Of Fibroblasts, Endothelial Cells and Macrophages In Bleomycin-Treated Mice
Abstract Number: 2823

FLIP Deficiency In Dendritic Cells Promotes Spontaneous Inflammatory and Erosive Arthritis
Abstract Number: 2557

Fluctuations In sVCAM-1 and Adiponectin Mirror Fluctuations In Disease Activity In Lupus, But Cannot Be Use To Accurately Predict Impending Changes In Disease State
Abstract Number: 2228

FMS-Like Tyrosine Kinase 3 Ligand -Dependent CD103+DC Are Crucial For The Initiation Of Collagen-Induced Arthritis
Abstract Number: 920

Fms-Like Tyrosine Kinase 3 Signaling Is Essential For Differentiation Of Antigen Specific Plasma Cells During Experimental Arthritis
Abstract Number: 209

Focus on cardiovascular Risk Factor Recording In a Rheumatology Outpatient Clinic
Abstract Number: 1711

Folic Acid Prescription Among Older Adult Methotrexate Initiators Is Poor

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].